English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The Eczema of the external auditory canal (EAC) is a challenge for the otolaryngologist and it’s a pathology that can annoy the patients and, in the most extreme cases, compromise their quality of life. Hence patients with eczema of EAC are exposed to a greater number of bacterial (acute bacterial otitis externa) or fungal (otomycosis) infections. The therapies proposed as of now for chronic eczematous external otitis (more than 3 months) are empirical. The most widely used drugs in this condition are topical corticosteroids which unfortunately can lead to dehydration of the skin, hypotropism with a reduction in their effectiveness over time  Ozoile® (Stable Ozonides with Vitamin E acetate) acts as a biological inducer, regulates the main metabolic pathways, stimulates the endogenous defense system and through the regulation of gene transcription promotes tissue regeneration and damage-injury repair. This biological inducer has anti-inflammatory, anti-itching and anti-microbial action. Based on these results, the author used Ozoile® for the treatment of chronic eczematous external otitis (symptoms lasting more than three months).  Sixty patients suffering from chronic eczematous otitis externa (CEOE) were recruited and given 1 month of treatment with 5 drops per ear in the morning and in the evening. Through a visual analogue scale (minimum score 0 and maximum 10 depending on the severity of the symptoms) the parameters itching, secretions, flaking and complications were evaluated at the beginning of the treatment (time 0) and at one month (time 1). After the treatment the results were as follow: 62.5% itching reduction, desquamation reduction by 72%, reduction of secretions by 80%. Total absence of side effects. We can conclude that Ozoile® (Stable Ozonides with Vitamin E acetate) has an excellent "outcome" in EAC eczema even for prolonged periods and is a manageable and complication-free biological inducer.

New therapeutic approach with ozoile® to the EAC eczema, a chronic and annoying pathology